menu
Webinar

Comprehensive genomic profiling from liquid biopsy samples

Join us as we discuss workflow and bioinformatics considerations when consolidating biomarker testing into a panel that enables CGP from liquid biopsy samples

Virtual Event (Webinar) | August 20, 2020 - August 20, 2020 | 12:00 - 13:00 (GMT-05) EST Add to Calendar
Register Now

About This Event

Clinical trials are increasingly using liquid biopsy samples to complement or as an alternative to invasive tissue sample collections. With the increasing complexity and diversity of biomarkers to include for clinical trials stratification, liquid biopsy panels that enable Comprehensive Genomic Profiling (CGP) allows consolidation of individual biomarkers into a single NGS assay. In addition, sophisticated bioinformatics solutions allow for the detection of variants at low allelic frequencies, making the assay suitable for biomarker development programs and clinical trial use. In this webinar, we will discuss critical workflow and bioinformatics considerations when consolidating biomarker testing into a panel that enables CGP from liquid biopsy samples in clinical trials.

Learning Objectives

  1. Trends contributing towards the use of panels enabling CGP testing from liquid biopsy samples in clinical trials
  2. Workflow and technical considerations when selecting a liquid biopsy CGP assay
  3. The requirements and impact of choosing a suitable bioinformatics solution to enable low frequency variants detection and meeting the needs of translational researchers

 
The Pathologist and Illumina are delighted to bring you this webinar with presentation by Stephanie Hastings, Ph.D, Q2 Solutions. 
 

Register for Event

Speakers

Stephanie B. Hastings, Ph.D.
Staff Scientist II, Assay Development, Translational Genomics

Stephanie B. Hastings, Ph.D., is a Staff Scientist II in Assay Development, Translational Genomics at Q2 Solutions | EA Genomics. In this role, she is responsible for the development and validation of genomic assays to support research and clinical programs. Stephanie is currently leading development efforts surrounding liquid biopsy applications as well as panel-based tumor mutational burden (TMB) next-generation sequencing (NGS) analyses. 

Stephanie has more than 10 years of experience across diverse disciplines including: clinical molecular diagnostics, animal health vaccine development, genetic engineering and protein biochemistry.

Stephanie earned a Bachelors degree in Microbiology from North Carolina State University, followed by a Ph.D. in Biochemistry and Molecular Biology at the University of Georgia